MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    The effect of Mozart piano sonata on Parkinsonian tremor, rigidity and bradykinesia

    A. Shoeybi, N. Olfati (Mashhad, Islamic Republic of Iran)

    Objective: In this study we intend to assess the effect of Mozart piano sonata on Parkinsonian tremor. Background: The effect of rhythmic auditory stimulation and…
  • 2016 International Congress

    Effects of safinamide in patients with Parkinson’s disease measured by Parkinson’s KinetiGraphTM

    I. Suttrup, V. Zentsch, J. Schroeder, T. Warnecke (Muenster, Germany)

    Objective: To objectively evaluate the effects of Safinamide in patients with Parkinson's (PD) by using the Parkinson's KinetiGraphTM (PKG), a newly developed tool for graphically…
  • 2016 International Congress

    Duodopa treatment experience in Oradea

    M. Sabau, L. Botnaru, A. Badea, C. Dudas (Oradea, Romania)

    Objective: We want to present our results in Duodopa treatment for advanced Parkinson's disease (PD). Background: A center for advanced PD was created in our…
  • 2016 International Congress

    Effectiveness of a multidisciplinary PD clinic in improving quality of life

    H.F. Chan, D.K.W. Chau, T. Fung, I. Chan, Y.F. Cheung, W.C. Fong (Hong Kong, Hong Kong)

    Objective: To evaluate the effectiveness of a multidisciplinary PD clinic in a tertiary hospital in Hong Kong. Background: Parkinson's disease (PD) has been recognized as…
  • 2016 International Congress

    Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3beta activity

    C.H. Lin, H.I. Lin, M.L. Chen, T.T. Lai, L.P. Cao, M.J. Farrer, R.M. Wu, C.T. Chien (Taipei, Taiwan)

    Objective: To identify disease-modifying therapy for LRRK2-G2019S parkinsonism. Background: Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of Parkinson's disease (PD) without…
  • 2016 International Congress

    Predicting therapeutic effects of atomoxetine and citalopram on response inhibition in Parkinson’s disease

    J.B. Rowe, C. Rae, C. Nombela, T. Ham, P. Vazquez, I. Coyle-Gilchrist, C.R. Housden, B.J. Sahakian, T.W. Robbins, Z. Yes (Cambridge, United Kingdom)

    Objective: (1) To reassess the behavioral impact of novel noradrenergic (atomoxetine) and serotonergic (citalopram) therapies for impulsivity and (2) to develop predictive models to identify…
  • 2016 International Congress

    Telemedicine facilitates efficient and safe home titration of levodopa/carbidopa intestinal gel (LCIG) in patients with advanced Parkinson’s disease

    T. Willows, N. Dizdar, D. Nyholm, H. Widner, P. Grenholm, U. Schmiauke, A. Urbom, K. Groth, J. Larsson, J. Permert, S. Kjellander (Huddinge, Sweden)

    Objective: To demonstrate feasibility of TM for LCIG home titration, evaluate resource use, and assess patient, neurologist and nurse satisfaction. Background: LCIG, is used for…
  • 2016 International Congress

    Safety, pharmacokinetics, and efficacy of levodopa prodrug ONO-2160/CD: A study in patients with Parkinson’s disease

    M. Nomoto, M. Nagai, N. Nishikawa, Y. Kagamiishi, K. Yano, M. Akisada, S. Saito, M. Yuba, A. Takeda (Tohon Ehime, Japan)

    Objective: The objective of this study was to evaluate the safety, pharmacokinetic profile, and efficacy of ONO-2160/carbidopa (CD) and to compare them with an immediate-release…
  • 2016 International Congress

    Effects of levodopa on adaptation of reactive stepping in people with Parkinson’s disease

    F.B. Horak, B. Dijstra, J.G. Nutt, D.S. Paterson (Portland, OR, USA)

    Objective: Participants with PD were able to improve postural stepping responses with practice and this learning was improved by levodopa. Background: Protective steps in response…
  • 2016 International Congress

    A double blind investigation of efficacy and safety of incobotulinumtoxinA in Parkinson’s disease tremor- A customized injection approach

    S.O. Mittal, R. Rostami, D.G. Machado, D. Richardson, B. Jabbari (Cleveland, OH, USA)

    Objective: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA) injection in the tremor of Parkinson's disease (PD). Background: Unlike other cardinal motor features of…
  • « Previous Page
  • 1
  • …
  • 1917
  • 1918
  • 1919
  • 1920
  • 1921
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley